

Minutes	
Title of Meeting:	Rotherham Place Board: ICB Business
Time of Meeting:	10.45 – 11.30am
Date of Meeting:	Wednesday 19 June 2024
Venue:	The John Smith Room, Rotherham Town Hall
Chair:	Chris Edwards
Contact for Meeting:	Lydia George: lydia.george@nhs.net/ Wendy Commons: wcommons@nhs.net
Apologies:	Richard Jenkins, Chief Executive, TRFT Sharon Kemp, Chief Executive, RMBC Toby Lewis, Chief Executive, RDaSH Dr Neil Thorman, Primary Care Representative, RPCCG Michael Wright, Deputy Chief Executive, The Rotherham NHS Foundation Trust Dr Anand Barmade, Medical Director, Connect Healthcare
Conflicts of Interest:	General declarations were acknowledged for Members as providers/commissioners of services.
Quoracy:	No business shall be transacted unless at least 60% of the membership (which equates to 3 individuals) and including the following are present: (1) Executive Place Director and (2) Independent Non-Executive Member.

Members Present:

Chris Edwards (**CE**), Chair, Executive Place Director, NHS SY ICB
 Dr Jason Page (**JP**), Medical Director, NHS SY ICB
 Claire Smith (**CS**), Deputy Place Director (Rotherham), NHS SY ICB
 Wendy Allott (**WA**), Director of Financial Transformation (Rotherham), NHS SY ICB
 Shahida Siddique (**SS**), Independent Non-Executive Member, NHS SY ICB

Participants:

Ben Anderson (**BA**), Director of Public Health, RMBC
 Shafiq Hussain (**SH**), Chief Executive, Voluntary Action Rotherham
 Penny Fisher (**PF**), General Manager, Community, Rotherham NHS Foundation Trust
 Lydia George (**LG**), Transformation & Partnership Portfolio Manager, NHS SY ICB
 Gordon Laidlaw (**GL**), Head of Communications (Rotherham), NHS SY ICB
 Andrew Russell (**AR**), Director of Nursing (Doncaster & Rotherham Place), NHS SY ICB
 Ian Spicer (**IS**), Strategic Director – Adult Care, RMBC
 Jude Wildgoose (**JW**), Assistant Director – Transformation & Delivery (Rotherham), NHS SY ICB
 Govinder Bhogal (**GB**), Programme Director for Medicines Optimisation, NHS SY ICB

In Attendance:

Wendy Commons, Business Support Officer (Rotherham), NHS SY ICB

Item Number	Discussion Items
i18/6/24	Place Performance Report
	<p>JW gave highlights from this month's performance report.</p> <p>On performance comparison against the national position:</p> <ul style="list-style-type: none"> - Rotherham is in first position out of 106 trusts nationally on diagnostics performance - With RTT (referral to treatment times) we have maintained performance but are better than the national position and continue to work towards target - On IAPT 6 week waits – Rotherham is still overperforming at 99% against the 75% target with self-referral contributing to this performance. <p>Other highlights included:</p> <ul style="list-style-type: none"> ➤ IAPT 18wk wait – performance consistently meeting the 95% target ➤ Cancer waiting times: <ul style="list-style-type: none"> • the 28 day faster diagnosis target achieved target but showed a slight reduction in performance on the previous month • 31 day standard was not achieved but showed an upward trajectory • The 62 day referral to treatment target - not met the national standard but also continues on an upward trajectory ➤ Referral to treatment times incomplete pathways as already mentioned but provisional data showed a slight increase on last month's performance supporting narrative ➤ There were 1034 patients who had been waiting over 52 weeks which was an increase on last month ➤ There were 20 specialties under the 92% standard, with just general medicine meeting the standard. std with significant increases in cardio thoracic surgery and thoracic medicine ➤ There had been 212 breaches for Rotherham patients, which broken down showed 30 at Rotherham Hospital with others waiting to be seen elsewhere. ➤ There had been a reduction in the number of cancelled operations ➤ The target for A&E 4 hr waits was reported at 66.9% against 76% target. Rotherham continues to benchmark well against other pilot sites. ➤ Yorkshire Ambulance Service handover times decreased performance on the 15 minute handovers but there had been a slight increase in performance with the over 30 and 60 minute handovers. <p>Members noted performance this month.</p> <p>JW and BA had discussed how to update the performance report and include some of the more important measures. A small working group will be formed to undertake the work with changes being proposed to Place Board for agreement.</p> <p>CS would like to add in some community measures, reflecting the unplanned pathway and welcome input from PF on the group.</p>
i19/6/24	Place Prescribing Report
	<p>Govinder Bhogal joined the meeting to update members on quarter 3 medicines management activity.</p> <ul style="list-style-type: none"> - Gov advised that Rotherham has experienced cost growth of 6.25% which is lower than England. However item growth is still higher than the England average.

- No cheaper stock obtainable (NCSO) issues cost over £1m by December and this is not something that we can predict or plan for.
- The highest cost growth was on drugs for diabetes, closely followed by lipid regulating drugs. This should be viewed as positive in part as it reflects that we are treating more in line with NICE guidelines.
- Some previously NSCO drugs have come back into circulation which have assisted with cost reductions as well as a reduction in antidepressant cost due in part to the Rotherham antidepressant reviews.
- Good progress has been made with the prescribing incentive scheme and Qipp savings have progressed as planned and are on target.
- The medicines safety dashboard is also progressing well and has been made simpler to use and understand.
- Rotherham has led the way with the management of non PBR drugs resulting in £1.5m saved for the ICB system.
- Updates were noted around medicines management projects ie, hypertension and lipid modification, nutritional prescribing, infant feeds, woundcare, diabetes, heart failure, antidepressant prescribing and the care home hydration project were reviewed and the good progress noted.

CE thanked GB for the comprehensive quarterly update and the good work taking place by the medicines optimisation team.

JP commented that the report doesn't reflect, quantify or take account of the work saved for clinicians and other colleagues through the introduction of some of the projects which could be really powerful to be able to demonstrate.

Emphasising that cost rises and prevention work are important, BA asked whether there are any costs that were not what we were expecting. GB replied that fluctuations in drug costs are unpredictable but the medicines optimisation team undertakes horizon scanning as much as is possible.

i20/6/24	ICB Board Assurance Framework, Risk Register & Issues Log
<p>Members received the risk register, issues log and board assurance framework for information.</p> <p>Members specifically noted the risks for Rotherham. Discussion followed around a period of downtime experienced following the move of IT servers from Oak House. The uploading of Rotherham files and folders had affected Rotherham Place users and business continuity. CE will review the impact and assess the risk with ICB colleagues at Rotherham Place Executive Team and update Rotherham Risk Register accordingly.</p> <p style="text-align: right;">Action: CE</p> <p>Place Board noted the business assurance framework, risk register and issues log.</p>	
i21/6/24	Feedback from Rotherham Place Executive Team (RPET)
<p>Members noted the decisions made at RPET.</p>	
i22/6/24	Minutes and Action Log from 15 May 2024 Meeting
<p>The minutes from the May meeting were accepted as a true and accurate record.</p> <p>The action log was reviewed and up to date.</p>	

i23/6/24	Communication to Partners
None.	
i24/6/24	Risks and Items for Escalation
None.	
i25/6/24	Future Agenda Items:
Standing Items <ul style="list-style-type: none"> – Rotherham Place Performance Report (monthly) – Risk Register (Monthly for information) – Place Medicines Management Report (Quarterly – next due August) – Quality, Patient Safety and Experience Dashboard (Bi- monthly – next due July) – Quarterly Medical Director Update (July) – JP 	
i26/6/24	Date of Next Meeting
The next meeting will take place on Wednesday 17 July 2024 at Rotherham Hospice.	

Membership

Chris Edwards (Chair)	Executive Place Director/Deputy Chief Executive, ICB	NHS South Yorkshire Integrated Care Board
Claire Smith	Deputy Place Director, Rotherham Place	NHS South Yorkshire Integrated Care Board
Wendy Allott	Director of Financial Transformation, Rotherham	NHS South Yorkshire Integrated Care Board
Andrew Russell	Chief Nurse, Rotherham & Doncaster Place	NHS South Yorkshire Integrated Care Board
Dr Jason Page	Medical Director, Rotherham Place	NHS South Yorkshire Integrated Care Board
Shahida Siddique	Independent Non-Executive Member	NHS South Yorkshire Integrated Care Board

Participants

Ben Anderson	Director of Public Health	Rotherham Metropolitan Borough Council
Shafiq Hussain	Chief Executive	Voluntary Action Rotherham
Richard Jenkins	Chief Executive	The Rotherham NHS Foundation Trust (TRFT)
Sharon Kemp	Chief Executive	Rotherham Metropolitan Borough Council
Toby Lewis	Chief Executive	Rotherham, Doncaster and South Humber NHS Foundation Trust (RDaSH)
Cllr Joanna Baker-Rogers	H&WB Board Joint Chair	Rotherham Health and Wellbeing Board
Dr Neil Thorman	Primary Care Representative	Rotherham Primary Care Collaborative Group
Dr Anand Barmade	Medical Director	Connect Healthcare Rotherham
Michael Wright	Deputy Chief Executive	The Rotherham NHS Foundation Trust
Sally Kilgariff	Chief Operating Officer	The Rotherham NHS Foundation Trust
Lydia George	Transformation & Partnership Portfolio Manager (Rotherham)	NHS South Yorkshire Integrated Care Board
Nicola Curley	Director of Children's Services	Rotherham Metropolitan Borough Council

Gordon Laidlaw	Head of Communications (Rotherham)	NHS South Yorkshire Integrated Care Board
Ian Spicer	Strategic Director, Adult Care/Deputy Chief Exec	Rotherham Metropolitan Borough Council
Julie Thornton	Care Group Director	Rotherham, Doncaster and South Humber NHS Foundation Trust (RDaSH)